WallStSmart

Meta Platforms Inc. (META)vsTNL Mediagene Ordinary Shares (TNMG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Meta Platforms Inc. generates 432652% more annual revenue ($214.96B vs $49.67M). META leads profitability with a 32.8% profit margin vs -167.9%. META earns a higher WallStSmart Score of 83/100 (A-).

META

Exceptional Buy

83

out of 100

Grade: A-

Growth: 9.3Profit: 10.0Value: 8.0Quality: 7.0
Piotroski: 3/9Altman Z: 2.88

TNMG

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 3.0
Piotroski: 4/9Altman Z: -7.25
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

METAUndervalued (+34.8%)

Margin of Safety

+34.8%

Fair Value

$897.73

Current Price

$539.03

$358.70 discount

UndervaluedFair: $897.73Overvalued

Intrinsic value data unavailable for TNMG.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

META6 strengths · Avg: 9.8/10
Market CapQuality
$1.59T10/10

Mega-cap, among the largest globally

Profit MarginProfitability
32.8%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
40.6%10/10

Strong operational efficiency at 40.6%

Revenue GrowthGrowth
33.1%10/10

Revenue surging 33.1% year-over-year

EPS GrowthGrowth
62.4%10/10

Earnings expanding 62.4% YoY

Return on EquityProfitability
26.1%9/10

Every $100 of equity generates 26 in profit

TNMG1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Areas to Watch

META1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TNMG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.01M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-164.6%2/10

ROE of -164.6% — below average capital efficiency

Free Cash FlowQuality
$-3.15M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : META

The strongest argument for META centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 32.8% and operating margin at 40.6%. Revenue growth of 33.1% demonstrates continued momentum.

Bull Case : TNMG

The strongest argument for TNMG centers on Price/Book.

Bear Case : META

The primary concerns for META are Piotroski F-Score.

Bear Case : TNMG

The primary concerns for TNMG are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 23.52 is elevated, increasing financial risk.

Key Dynamics to Monitor

META profiles as a growth stock while TNMG is a turnaround play — different risk/reward profiles.

META carries more volatility with a beta of 1.25 — expect wider price swings.

META is growing revenue faster at 33.1% — sustainability is the question.

META generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

META scores higher overall (83/100 vs 32/100), backed by strong 32.8% margins and 33.1% revenue growth. Both earn "Exceptional Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Meta Platforms Inc.

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, PCs, virtual reality headsets, wearables and home devices around the world. The company is headquartered in Menlo Park, California.

Visit Website →

TNL Mediagene Ordinary Shares

COMMUNICATION SERVICES · PUBLISHING · USA

TNL Mediagene Ordinary Shares is an innovative biopharmaceutical firm focused on developing and commercializing cutting-edge therapies for oncology and autoimmune disorders. The company boasts a strong pipeline driven by advanced technologies and strategic collaborations, positioning it for significant growth in the evolving healthcare market. TNL Mediagene's commitment to scientific excellence and patient-centered solutions reinforces its aim to enhance patient outcomes while addressing critical health challenges, thereby establishing itself as a notable entity within the biopharmaceutical landscape.

Visit Website →

Want to dig deeper into these stocks?